3D printer produces implantable cartilage

Researchers from Chalmers University of Technology and Sahlgrenska Academy in Sweden have successfully used 3D printing to produce human cartilage cells capable of living and growing in mice. This development, announced in Plastic and Reconstructive Surgery Global Open, may be able to one day provide patients with body parts through 3D printing.

Using a 3D printer produced by Celllink, researchers printed a mix of nanocellulose and human cartilage cells. This mix was implanted in mice and was able to grow human cartilage tissue, form blood vessels and show strong stimulation of proliferation and neocartilage formation by human stem cells.

"This is the first time anyone has printed human-derived cartilage cells, implanted them in an animal model and induced them to grow," said Paul Gatenholm, professor of biopolymer technology at Chalmers University of Technology. "We now have proof that the 3D-printed hydrogel with cells can be implanted. It grows in mice and, in addition, blood vessels have formed in it.”

After 60 days of growth, the cells begin to show a resemblance to human cartilage. The cells are able to act as normal human cells. Cell division is furthered by adding stem cells.

"With what we have done, the research has taken a step forward towards someday, we hope, being able to bioprint cells that become body parts for patients,” said Gatenholm. “This is how you have to work when it comes to this kind of pioneering activity: one small step at a time. Our results are not a revolution—but they are a gratifying part of an evolution!"

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.